Tumor-suppressing roles of miR-214 and miR-218 in breast cancer

Oncology Reports

Volumn 35, Issue 6, 2016, Pages 3178-3184

  Liu, Bo ^a   Tian, Yanfeng ^a   Li, Fang ^a   Zhao, Zengren ^a   Jiang, Xia ^a   Zhai, Congjie ^a   Han, Xiaodong ^a   Zhang, Like ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cell apoptosis; Cell cycle; Cell migration; Cell proliferation; Microrna; MIR 214; MIR 218

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICRORNA; MICRORNA 125B; MICRORNA 206; MICRORNA 210; MICRORNA 214; MICRORNA 218; MICRORNA 335; MICRORNA 373; MICRORNA 494; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG; MIRN214 MICRORNA, HUMAN; MIRN218 MICRORNA, HUMAN; TUMOR MARKER;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER STAGING; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR VOLUME; BREAST TUMOR; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LYMPHATIC METASTASIS; MCF-7 CELLS; MICRORNAS; MIDDLE AGED;

EID: 84964907027     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4749     Document Type: Article

References (59)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Fentiman IS, Fourquet A and Hortobagyi GN: Male breast cancer. Lancet 367: 595-604, 2006.
3. Kroemer G, Senovilla L, Galluzzi L, André F and Zitvogel L: Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 21: 1128-1138, 2015.
4. Spanheimer PM, Carr JC, Thomas A, Sugg SL, Scott-Conner CE, Liao J and Weigel RJ: The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg 206: 2-7, 2013.
5. Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840, 2010.
6. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773, 2005.
7. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
8. Jiang X, Kanda T, Wu S, Nakamura M, Miyamura T, Nakamoto S, Banerjee A and Yokosuka O: Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. World J Gastroenterol 20: 7197-7206, 2014.
9. O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2010.
10. Sakurai M, Masuda M, Miki Y, Hirakawa H, Suzuki T and Sasano H: Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients. Int J Biol Markers 30: E190-e199, 2015.
11. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
12. Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo- Patiño MJ, Haz-Conde M, Santamarina I, Figueroa A, Antón-Aparicio LM and Valladares-Ayerbes M: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer 15: 297, 2015.
13. Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, Luo Y, Shi Y, Wang K, et al: miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 433: 207-212, 2013.
14. Gao Y, Zeng F, Wu JY, Li HY, Fan JJ, Mai L, Zhang J, Ma DM, Li Y and Song FZ: MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. Tumour Biol 36: 2875-2883, 2015.
15. Song L, Liu D, Wang B, He J, Zhang S, Dai Z, Ma X and Wang X: miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway. Oncol Rep 34: 525-531, 2015.
16. Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H, Zhang S, Hong R and Gu X: The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. Tumour Biol 36: 7185-7194, 2015.
17. Liu J, Mao Q, Liu Y, Hao X, Zhang S and Zhang J: Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res 25: 46-54, 2013.
18. Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching PA, et al: Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. Breast Cancer Res Treat 147: 61-68, 2014.
19. Yang X, Wang X, Shen H, Deng R and Xue K: Combination of mir-21 with circulating tumor cells markers improve diagnostic specificity of metastatic breast cancer. Cell Biochem Biophys 73: 87-91, 2015.
20. Han X, Yan S, Weijie Z, Feng W, Liuxing W, Mengquan L and Qingxia F: Critical role of miR-10b in transforming growth factor-β1-induced epithelial-mesenchymal transition in breast cancer. Cancer Gene Ther 21: 60-67, 2014.
21. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T and Sartorelli V: Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 32: 1607-1614, 2011.
22. Han G, Fan M and Zhang X: microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun 456: 804-809, 2015.
23. Dong Y, Zou J, Su S, Huang H, Deng Y, Wang B and Li W: MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. Mol Med Rep 12: 1016-1022, 2015.
24. Zhang Y, Han D, Wei W, Cao W, Zhang R, Dong Q, Zhang J, Wang Y and Liu N: MiR-218 inhibited growth and metabolism of human glioblastoma cells by directly targeting E2F2. Cell Mol Neurobiol 35: 1165-1173, 2015.
25. Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life 61: 1075-1082, 2009.
26. Peng RQ, Wan HY, Li HF, Liu M, Li X and Tang H: MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N- Acetyl-α-D-galactosamine:polypeptide N- Acetylgalactosaminyltransferase 7. J Biol Chem 287: 14301-14309, 2012.
27. Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY and Sun BC: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol 43: 632-641, 2011.
28. Zhang XJ, Ye H, Zeng CW, He B, Zhang H and Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 3: 46, 2010.
29. Duan Q, Wang X, Gong W, Ni L, Chen C, He X, Chen F, Yang L, Wang P and Wang DW: ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One 7: E31518, 2012.
30. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, Lee YS, Yen TC and Hsieh SY: MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol 57: 584-591, 2012.
31. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 71: 5765- 5778, 2011.
32. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 71: 2381- 2391, 2011.
33. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama K, Seki N, et al: miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol 39: 13-21, 2011.
34. Cheng Y, Yang X, Deng X, Zhang X, Li P, Tao J and Lu Q: MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1. Tumour Biol 36: 8015-8023, 2015.
35. Wang J, Zhang X, Wang L, Yang Y, Dong Z, Wang H, Du L and Wang C: MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer. PLoS One 10: E0118086, 2015.
36. Zhang LL, Guo YJ, Zhao CN and Gao JY: Effects and mechanism of miR-214 on hepatocellular carcinoma. Asian Pac J Trop Med 8: 392-398, 2015.
37. Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z and Jiang J: MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem Biophys Res Commun 428: 525-531, 2012.
38. Yamane K, Jinnin M, Etoh T, Kobayashi Y, Shimozono N, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T, et al: Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med Berl 91: 69-81, 2013.
39. Wen Z, Lei Z, Jin-An M, Xue-Zhen L, Xing-Nan Z and Xiu-Wen D: The inhibitory role of miR-214 in cervical cancer cells through directly targeting mitochondrial transcription factor A (TFAM). Eur J Gynaecol Oncol 35: 676-682, 2014.
40. Long LM, He BF, Huang GQ, Guo YH, Liu YS and Huo JR: microRNA-214 functions as a tumor suppressor in human colon cancer via the suppression of ADP-ribosylation factor-like protein 2. Oncol Lett 9: 645-650, 2015.
41. Song L, Li D, Zhao Y, Gu Y, Zhao D, Li X, Bai X, Sun Y, Zhang X, Sun H, et al: miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression. Tumour Biol: Sep 26, 2015 (Epub ahead of print).
42. Cao Q, Dong P, Wang Y, Zhang J, Shi X and Wang Y: miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D. Oncol Rep 33: 2606-2612, 2015.
43. Jun GJ, Zhong GG and Ming ZS: miR-218 inhibits the proliferation of glioma U87 cells through the inactivation of the CDK6/cyclin D1/p21Cip1/Waf1 pathway. Oncol Lett 9: 2743-2749, 2015.
44. Wang T, Chen T, Niu H, Li C, Xu C, Li Y, Huang R, Zhao J and Wu S: MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1. Int J Mol Med 36: 93-102, 2015.
45. Heishima K, Mori T, Sakai H, Sugito N, Murakami M, Yamada N, Akao Y and Maruo K: MicroRNA-214 promotes apoptosis in canine hemangiosarcoma by targeting the COP1-p53 axis. PLoS One 10: E0137361, 2015.
46. Phatak P, Byrnes KA, Mansour D, Liu L, Cao S, Li R, Rao JN, Turner DJ, Wang JY and Donahue JM: Overexpression of miR- 214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1. Oncogene: doi:10.1038/onc.2015.271 (Epub ahead of print).
47. Li PL, Zhang X, Wang LL, Du LT, Yang YM, Li J and Wang CX: MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis 36: 1484-1493, 2015.
48. He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H and Zhang X: MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biol 36: 2065-2075, 2015.
49. Xia H, Yan Y, Hu M, Wang Y, Wang Y, Dai Y, Chen J, Di G, Chen X and Jiang X: MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity. Neuro Oncol 15: 413-422, 2013.
50. Jin Y, Yang CJ, Xu X, Cao JN, Feng QT and Yang J: MiR-214 regulates the pathogenesis of patients with coronary artery disease by targeting VEGF. Mol Cell Biochem 402: 111-122, 2015.
51. Yang TS, Yang XH, Wang XD, Wang YL, Zhou B and Song ZS: MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int 13: 68, 2013.
52. Liu Z, Xu Y, Long J, Guo K, Ge C and Du R: microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J Cancer Res 27: 247-257, 2015.
53. Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci 105: 802-811, 2014.
54. Jin J, Cai L, Liu ZM and Zhou XS: miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev 14: 3681-3684, 2013.
55. Lee TS, Lin JJ, Huo YN and Lee WS: Progesterone inhibits endothelial cell migration through suppression of the rho activity mediated by cSrc activation. J Cell Biochem 116: 1411- 1418, 2015.
56. van der Horst PH, Wang Y, Vandenput I, Kühne LC, Ewing PC, van Ijcken WF, van der Zee M, Amant F, Burger CW and Blok LJ: Progesterone inhibits epithelial- To-mesenchymal transition in endometrial cancer. PLoS One 7: E30840, 2012.
57. Bokhari AA, Lee LR, Raboteau D, Hamilton CA, Maxwell GL, Rodriguez GC and Syed V: Progesterone inhibits endometrial cancer invasiveness by inhibiting the TGFβ pathway. Cancer Prev Res (Phila) 7: 1045-1055, 2014.
58. Xie M, Zhou L, Chen X, Gainey LO, Xiao J, Nanes MS, Hou A, You S and Chen Q: Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells. BioMed Res Int 2015: 426429, 2015.
59. Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M and Dong X: Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One 9: E92714, 2014.